Context Therapeutics
CNTX
42 hedge funds and large institutions have $43.7M invested in Context Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 12 closing their positions.
17.46% less ownership
Funds ownership: 97.06% → 79.61% (-17%)
19% less funds holding
Funds holding: 52 → 42 (-10)
43% less capital invested
Capital invested by funds: $76.4M → $43.7M (-$32.7M)
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
83% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$879K |
| 2 |
SC
Shay Capital
New York
|
+$122K |
| 3 |
Renaissance Technologies
New York
|
+$75.8K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$13.6K |
| 5 |
CWM
Congress Wealth Management
Boston,
Massachusetts
|
+$13.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$608K |
| 2 |
ABG
Ally Bridge Group
New York
|
-$365K |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$309K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$213K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$210K |
CNTX Hedge Fund Activity: Q1 2025 in Review
42 of the 7,463 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q1 2025, worth a combined $43.7M — down 43% from $76.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CNTX and 2 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 6 added.
The largest buyer was Blue Owl Capital Holdings, adding an estimated $879K. The largest seller was UBS Group, cutting an estimated $608K.
- 42 institutional investors held Context Therapeutics (CNTX) as of Q1 2025, down from 52 in Q4 2024.
- Funds reported $43.7M of Context Therapeutics stock for Q1 2025, down 43% quarter-over-quarter.
- 2 funds opened new Context Therapeutics positions in Q1 2025 and 12 closed out, a net change of -10 holders.
- The largest Context Therapeutics buyer in Q1 2025 was Blue Owl Capital Holdings, an estimated $879K added.
- The largest Context Therapeutics seller in Q1 2025 was UBS Group, an estimated $608K sold.
Based on aggregated 13F filings for Q1 2025.